Cardiac Biomarker Panels: ST2, Troponin and D-dimer

Updated 2026-09-28

How the three work together in cardiovascular research and diagnostics, and why raw-material quality decides assay reliability.

The trio

sST2 signals cardiac stress and remodelling; troponin (cTnI or cTnT) signals myocardial injury; D-dimer reflects fibrin turnover and thrombosis. Together they cover stress, injury and coagulation in cardiovascular work.

Why they are read together

A patient can show injury without stress, or stress without injury. Combining markers gives a fuller picture in heart-failure and acute-coronary research than any single analyte.

Raw-material quality decides the assay

Each marker needs high-purity antigen and consistent lots to stay reproducible across calibrators, controls and samples. This is where the supplier becomes part of your data quality.

What the guideline literature says about each marker

The three markers in this panel sit at different levels of clinical maturity, and it helps to know which is which before you design a study around them. Cardiac troponin is the reference standard for myocardial injury: the Fourth Universal Definition of Myocardial Infarction sets out the analytical and clinical criteria, and the analytical characteristics of high-sensitivity assays are themselves the subject of detailed guidance. Natriuretic peptides occupy a similarly established position in heart failure, with practical guidance describing how their concentrations should be interpreted and where they mislead. sST2 is further along the adoption curve — supported by mechanism, by prognostic studies and by a published consensus statement, but used as a complementary marker rather than a frontline test. D-dimer is a different case again: a coagulation assay whose clinical value depends heavily on the assay format and on the pre-test probability of the population in front of it.

What this means for the raw material you order

Each marker has a different analytical weak point, and that weak point should drive your specification rather than the price list. Cardiac troponin assays are not fully harmonised across platforms, so the form and origin of the antigen used as calibrator is a development decision with consequences you will live with. Natriuretic peptide assays are affected by glycosylation of the analyte, which pushes the question towards epitope placement and away from a general purity figure. sST2 is comparatively well-behaved analytically, which is exactly why lot-to-lot consistency becomes the dominant risk — there is nothing else for it to hide behind. D-dimer is not a single molecular species at all but a family of cross-linked fibrin degradation products, so the origin of the antigen and the specificity of the antibody define what your assay actually measures.

Ask a technical question